BBNX vs DXCM
BBNX: Beta Bionics is a medical technology company developing automated insulin delivery systems to simplify diabetes management and improve patient outcomes. DXCM: Dexcom is a leading medical technology company specializing in continuous glucose monitoring (CGM) systems that help people with diabetes manage their condition with real-time data.
Side-by-side fundamentals
| Metric | BBNX | DXCM | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $17.74 | $85.74 | |
| Market cap | $798M | $32.4B | |
| P/E as of 2026-10-20 | n/a | 33.89 | |
| PEG as of 2026-10-20, 3-year EPS CAGR to FY2025 | n/a | 0.93 | |
| Net margin FY2025, SEC XBRL | -73.0% | +17.9% | DXCM higher |
| Gross margin FY2025, SEC XBRL | +55.4% | +60.1% | DXCM higher |
| Operating margin FY2025, SEC XBRL | -71.5% | +19.6% | DXCM higher |
| ROE FY2025, SEC XBRL | -25.5% | +30.5% | DXCM higher |
| ROA FY2025, SEC XBRL | -22.3% | +13.2% | DXCM higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +53.9% | +15.6% | BBNX higher |
| Revenue CAGR (3y) SEC XBRL | +189.1% | +17.0% | BBNX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.68 | 0.89 | |
| 1-year return as of 2026-10-20 close | -12.4% | +25.3% | DXCM higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.